3D Systems Corp Earnings Call Signals Turnaround Momentum

3D Systems Corp ((DDD)) has held its Q1 earnings call. Read on for the main highlights of the call.

3D Systems Corp’s latest earnings call struck a cautiously optimistic tone, as management showcased a clear return to growth and sharp cost discipline while acknowledging near‑term turbulence. Revenue and margins are moving in the right direction, key verticals are accelerating, and new products are gaining traction, even as geopolitical tensions and logistics issues temper the pace of improvement.

Return to Revenue Growth

3D Systems reported Q1 revenue of $95.5 million, an 11% increase year over year that marked a convincing return to top‑line expansion. The rebound was driven by strength in Med Tech, Dental, and Aerospace & Defense, underscoring management’s focus on higher‑value, application‑driven markets rather than broad, low‑margin hardware sales.

Healthcare Segment Outperformance

Healthcare Solutions was the standout performer, with revenue rising 21% year over year to $50.1 million and becoming the larger of the company’s two segments. Growth came from printers, materials, and especially medical parts such as titanium spinal and joint implants, signaling deepening adoption of additive manufacturing in complex, regulated medical applications.

Aerospace & Defense Momentum

Within Industrial Solutions, Aerospace & Defense delivered more than 20% revenue growth year over year, reinforcing its role as a key long‑term growth engine. Management tied this strength to its expectation that the Aero & Defense business can surpass 20% growth in 2026 and reach roughly $35 million in annual revenue as large programs ramp.

Product and Materials Growth

Across the portfolio, printers, materials, and parts manufacturing all posted double‑digit growth, highlighting balanced demand rather than a single‑product spike. Dental materials were particularly strong, with solid traction in aligners and Vertex prosthetic materials, while metal printer sales rose, supported by increased demand for the DMP 350 platform.

NextDent 300 Denture Platform Traction

The NextDent 300 jetted denture system is emerging as a breakthrough product, with labs such as ROE Dental reportedly tripling capacity on the back of the platform. Management noted U.S. approval targeted for 2025 and EU Phase IIa approval arriving two months ahead of schedule, expanding its addressable market to more than 60 million edentulous patients.

Gross Margin Expansion and Cost Savings

Non‑GAAP gross margin climbed to 36.1% in Q1, up roughly six percentage points from a year earlier on an adjusted basis, reflecting better factory utilization and a richer mix of consumables and higher‑margin printers. The company has now delivered more than $55 million in annualized cost savings, giving it more room to invest while protecting profitability.

Operating Expense Reduction and R&D Shift

First‑quarter non‑GAAP operating expenses fell to $36.6 million, down 35% year over year after adjusting for divestitures, a reduction management called structurally significant. With major, R&D‑heavy product refreshes largely complete, the company expects research spending to normalize at a more balanced level while maintaining innovation.

Adjusted EBITDA and EPS Improvement

Profitability metrics showed marked improvement as adjusted EBITDA turned positive at $2.1 million, a swing of $26 million from the prior year, or $28.2 million excluding divestitures. Non‑GAAP loss per share narrowed sharply to a $0.01 loss versus $0.21 a year ago, though management cautioned that quarterly results may remain somewhat volatile.

Cash Position and Balance Sheet Flexibility

3D Systems ended Q1 with $86.5 million in total cash, including cash, equivalents, and restricted balances, providing a cushion as it executes its turnaround. Debt maturities are staggered, with just $3.9 million due in late 2026 and about $92 million maturing in 2030, supporting management’s emphasis on disciplined capital allocation over the next several years.

Capacity Expansion and Technology Investment

To support growing aerospace demand, the company is expanding its Littleton facility by 80,000 square feet, with a grand opening expected in late summer to scale metal part production. In parallel, it continues to invest in technology through a $28 million government‑supported program aimed at next‑generation large‑format metal printers, positioning it for future industrial opportunities.

Backlog Build and Raised Production Targets

The early success of the denture platform has translated into a solid order backlog entering Q2, giving added visibility to second‑half revenue. Based on that momentum, management raised internal production targets for the back half of the year, suggesting confidence in both customer demand and its ability to deliver at scale.

Regional Supply Chain and Logistics Challenges

Geopolitical conflict in the Middle East has created regional supply‑chain and logistics bottlenecks, weighing on deliveries and demand, particularly in the jewelry business. These disruptions had modest negative effects on overall operations and serve as a reminder that the company’s global footprint exposes it to localized shocks.

Isolated Customer Disruption

Q1 results were also dented by lower‑than‑expected sales to one key medical customer due to a temporary internal issue at that client, partially offsetting gains in Med Tech printer revenue. Management indicated that the disruption has been resolved and expects sales to this customer to recover in Q2, helping normalize segment performance.

Cautious Near‑Term Guidance and Seasonality

Guidance for Q2 was deliberately conservative, with revenue projected between $93 million and $95 million, roughly flat to slightly below Q1, and an adjusted EBITDA loss of $2 million to $4 million. Management cited normal seasonal softness in Healthcare and broader macro uncertainty as reasons to guide cautiously, despite underlying operational progress.

Modest FX and Cost Headwinds

The company continues to face modest pressure from foreign exchange, tariffs, and certain supply‑chain‑related costs, which partially offset its gross‑margin gains. While not material enough to derail the turnaround, these headwinds could limit how quickly improvements in pricing, mix, and cost reductions reach the bottom line.

Remaining Net Loss and Profitability Path

Despite the substantial progress, 3D Systems still reported a small non‑GAAP net loss per share of $0.01 in Q1 and acknowledged that results will fluctuate quarter to quarter. Management nevertheless framed the positive EBITDA and sharply lower losses as evidence that the business is moving steadily toward sustainable profitability.

Concentration and Execution Risks

The company’s growth strategy leans heavily on a handful of high‑value sectors and major customers, including dental labs and aerospace accounts, which heightens concentration risk if any slow or reallocate spending. Executing on manufacturing scale‑up, backlog conversion, and timely logistics amid geopolitical volatility will be critical to maintaining investor confidence.

Forward‑Looking Guidance and Strategic Outlook

Looking ahead, management reiterated its objective of achieving breakeven or better adjusted EBITDA for the full year, supported by stable operating expenses and cost‑reduction programs expected to be complete by the end of Q2. They also highlighted long‑term growth drivers, including more than 20% projected growth in Aerospace & Defense by 2026 and a significantly expanded denture market targeting over 60 million potential patients.

3D Systems’ earnings call painted a picture of a company rebuilding momentum through focused end markets, tighter cost control, and promising new products, even as near‑term challenges keep management cautious. For investors, the story is one of improving fundamentals and growing strategic optionality, balanced against execution risks and the need to prove that recent gains can translate into durable, profitable growth.